7 Mar 2024 • In a Chicago-based cohort study involving 4,807 participants aged 72 on average, statin initiation demonstrated a 19% reduced risk of incident Alzheimer's disease (AD).

Notably, the protective effect was more pronounced (40% reduction) among individuals carrying the APOE ε4 allele. The study also revealed a slower annual decline in global cognition and episodic memory in APOE ε4 carriers on statins. Non-carriers showed no significant cognitive benefits.

The findings underscore a potential association between statins and lower AD risk, especially in those with the APOE ε4 allele.

Source: AAN | Read full story